Stay updated with breaking news from Kronos Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) CEO Norbert W. Bischofberger acquired 1,378,901 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were acquired at an average cost of $0.88 per share, with a total value of $1,213,432.88. Following the transaction, the chief executive officer now directly […]
—KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed—
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 -- Kronos Bio, Inc. , a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by...
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 -- Kronos Bio, Inc. , a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by...
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small...